207 related articles for article (PubMed ID: 30372384)
21. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma.
Liu C; Cao F; Xing W; Si T; Yu H; Yang X; Guo Z
Int J Hyperthermia; 2019; 36(1):220-228. PubMed ID: 30663911
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.
Sepe P; Mennitto A; Corti F; Procopio G
Immunotargets Ther; 2020; 9():273-288. PubMed ID: 33224904
[TBL] [Abstract][Full Text] [Related]
23. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
24. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
25. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
26. Towards individualized therapy for metastatic renal cell carcinoma.
Kotecha RR; Motzer RJ; Voss MH
Nat Rev Clin Oncol; 2019 Oct; 16(10):621-633. PubMed ID: 30992569
[TBL] [Abstract][Full Text] [Related]
27. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E; Walker CL; Rathmell WK
Nat Rev Nephrol; 2021 Apr; 17(4):245-261. PubMed ID: 33144689
[TBL] [Abstract][Full Text] [Related]
28. Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC).
Li K; Li D; Hafez B; Bekhit MMS; Jardan YAB; Alanazi FK; Taha EI; Auda SH; Ramzan F; Jamil M
Oncol Res; 2024; 32(4):737-752. PubMed ID: 38560573
[TBL] [Abstract][Full Text] [Related]
29. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.
Jiang A; Pang Q; Gan X; Wang A; Wu Z; Liu B; Luo P; Qu L; Wang L
Cancer Innov; 2022 Aug; 1(2):146-167. PubMed ID: 38090653
[TBL] [Abstract][Full Text] [Related]
30. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies.
Jing J; Wu Z; Wang J; Luo G; Lin H; Fan Y; Zhou C
Signal Transduct Target Ther; 2023 Aug; 8(1):315. PubMed ID: 37596267
[TBL] [Abstract][Full Text] [Related]
31. Construction of a two-gene prognostic model related to ferroptosis in renal cell carcinoma.
Li L; Xu Y; Yang W; Zhang K; Zhang Z; Zhou J; Gong Y; Gong K
Transl Androl Urol; 2023 Jul; 12(7):1167-1183. PubMed ID: 37554538
[TBL] [Abstract][Full Text] [Related]
32. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
33. Obesity and renal cell carcinoma: Biological mechanisms and perspectives.
Venkatesh N; Martini A; McQuade JL; Msaouel P; Hahn AW
Semin Cancer Biol; 2023 Sep; 94():21-33. PubMed ID: 37286114
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma.
Bao JM; Zhi X; Yuan HY; Chen TY; Chen MK; Zhou JH; Xue KY; Yang JK; Liu CD
Transl Cancer Res; 2023 Mar; 12(3):572-584. PubMed ID: 37033345
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis and its application in different cancers: an overview.
Xu L; Liu K; Wang F; Su Y
Mol Cell Biochem; 2023 Dec; 478(12):2683-2693. PubMed ID: 36914880
[TBL] [Abstract][Full Text] [Related]
36. The Decision to Surgically Resect Recurrent Renal Cell Carcinoma: More Evidence that Careful Case Selection by Surgeons Is Associated with Better Survival.
Russo P
Eur Urol Open Sci; 2023 Mar; 49():90-91. PubMed ID: 36785748
[No Abstract] [Full Text] [Related]
37. Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma.
Zheng A; Bai J; Ha Y; Yu Y; Fan Y; Liang M; Lu Y; Shen Z; Luo B; Jie W
BMC Cancer; 2023 Feb; 23(1):135. PubMed ID: 36759775
[TBL] [Abstract][Full Text] [Related]
38. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
39. A novel autophagy-related long non-coding RNAs prognostic risk score for clear cell renal cell carcinoma.
Tang F; Tang Z; Lu Z; Cai Y; Lai Y; Mai Y; Li Z; Lu Z; Zhang J; Li Z; He Z
BMC Urol; 2022 Dec; 22(1):203. PubMed ID: 36496360
[TBL] [Abstract][Full Text] [Related]
40. Small molecule inhibitors targeting the cancers.
Liu GH; Chen T; Zhang X; Ma XL; Shi HS
MedComm (2020); 2022 Dec; 3(4):e181. PubMed ID: 36254250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
